Clinical Trial Update: Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating pembrolizumab in combination with the IMA950 multipeptide vaccine and Poly-ICLC adjuvant for relapsing glioblastoma has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• IMA950
• Pembrolizumab (pembrolizumab)
• Poly-ICLC (poly-ICLC)

Snippet

Sponsor: University Hospital, Geneva | Conditions: Glioblastoma Multiforme, Glioblastoma, Adult | Phase 1, Phase 2 | Status: COMPLETED